{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:40:00Z","timestamp":1791258000342,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024YFFK0012"],"award-info":[{"award-number":["2024YFFK0012"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01541-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:33:39Z","timestamp":1747197219000},"page":"646-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia"],"prefix":"10.1007","volume":"43","author":[{"given":"Liqiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"publisher","unstructured":"Palmieri R, Candoni A, Di Raimondo F et al (2025) Navigating acute myeloid leukemia towards better outcomes: treatment pathways and challenges for patients ineligible for intensive chemotherapy. Blood Rev 101288. https:\/\/doi.org\/10.1016\/j.blre.2025.101288","DOI":"10.1016\/j.blre.2025.101288"},{"key":"1541_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100:860\u2013891. https:\/\/doi.org\/10.1002\/ajh.27625","journal-title":"Am J Hematol"},{"key":"1541_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99:615\u2013624. https:\/\/doi.org\/10.1002\/ajh.27246","journal-title":"Am J Hematol"},{"key":"1541_CR4","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"1541_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"1541_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"1541_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/biomedicines11020359","volume":"11","author":"A Sperotto","year":"2023","unstructured":"Sperotto A, Bochicchio MT, Simonetti G et al (2023) Measurable residual disease and clonal evolution in acute myeloid leukemia from diagnosis to post-transplant follow-up: the role of next-generation sequencing. Biomed 11:359. https:\/\/doi.org\/10.3390\/biomedicines11020359","journal-title":"Biomed"},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12935-024-03368-4","volume":"24","author":"N Kim","year":"2024","unstructured":"Kim N, Hahn S, Choi YJ et al (2024) Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int 24:174. https:\/\/doi.org\/10.1186\/s12935-024-03368-4","journal-title":"Cancer Cell Int"},{"key":"1541_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300637","volume":"19","author":"HJ Han","year":"2024","unstructured":"Han HJ, Choi K, Suh HS (2024) Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study. PLoS ONE 19:e0300637. https:\/\/doi.org\/10.1371\/journal.pone.0300637","journal-title":"PLoS ONE"},{"key":"1541_CR10","doi-asserted-by":"publisher","unstructured":"Zhao L, Zhao J, Zhong K et al (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","DOI":"10.1038\/s41392-022-00966-4"},{"key":"1541_CR11","doi-asserted-by":"publisher","unstructured":"Li X, Song Y (2020) Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol 13. https:\/\/doi.org\/10.1186\/s13045-020-00885-3","DOI":"10.1186\/s13045-020-00885-3"},{"key":"1541_CR12","doi-asserted-by":"publisher","unstructured":"Chen C, Feng Y, Zhou C et al (2024) Development of natural product-based targeted protein degraders as anticancer agents. Bioorg Chem 153. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107772","DOI":"10.1016\/j.bioorg.2024.107772"},{"key":"1541_CR13","doi-asserted-by":"publisher","unstructured":"Hu Y, Yan Y, Wang J et al (2024) Molecular glue degrader for tumor treatment. Front Oncol 14. https:\/\/doi.org\/10.3389\/fonc.2024.1512666","DOI":"10.3389\/fonc.2024.1512666"},{"key":"1541_CR14","doi-asserted-by":"publisher","unstructured":"Long X, Zhao L, Li G, et al (2021) Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3\u03b2\/CyclinD1 pathway. Aging 13. https:\/\/doi.org\/10.18632\/aging.202796","DOI":"10.18632\/aging.202796"},{"key":"1541_CR15","doi-asserted-by":"crossref","unstructured":"Sellar RS, Sperling AS, Stabicki M et al (2022) Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. J Clin Invest 132","DOI":"10.1172\/JCI153514"},{"key":"1541_CR16","doi-asserted-by":"publisher","unstructured":"Matyskiela ME, Lu G, Ito T et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535. https:\/\/doi.org\/10.1038\/nature18611","DOI":"10.1038\/nature18611"},{"key":"1541_CR17","unstructured":"Chengdu FenDi Pharmaceutical Co., Ltd. (2024) A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and initial efficacy of FD-001 in patients with relapsed or refractory hematological malignancies. https:\/\/clinicaltrials.gov.\u00a0Accessed 12 Mar 2025"},{"key":"1541_CR18","unstructured":"Celgene (2024) A phase 1, open-label, dose finding study of CC-90009, a novel cereblon E3 ligase modulating drug, in subjects with relapsed or refractory acute myeloid leukemia or relapsed or refractory higher-risk myelodysplastic syndromes. https:\/\/clinicaltrials.gov.\u00a0Accessed 12 Mar 2025"},{"key":"1541_CR19","unstructured":"Monte Rosa Therapeutics, Inc (2025) A phase 1/2 study of oral MRT-2359 in patients with MYC-Driven and other selected solid tumors including lung cancer and diffuse B-Cell lymphoma. https:\/\/clinicaltrials.gov.\u00a0Accessed 12 Mar 2025"},{"key":"1541_CR20","unstructured":"Biotheryx, Inc. (2023) An open label, escalating multiple dose study to evaluate the safety, toxicity, pharmacokinetics, and preliminary activity of BTX-1188 in subjects with advanced malignancies. https:\/\/clinicaltrials.gov.\u00a0Accessed 12 Mar 2025"},{"key":"1541_CR21","doi-asserted-by":"publisher","unstructured":"Paudel RR, Lu D, Chowdhury SR et al (2023) Targeted protein degradation via lysosomes. Biochem 62. https:\/\/doi.org\/10.1021\/acs.biochem.2c00310","DOI":"10.1021\/acs.biochem.2c00310"},{"key":"1541_CR22","doi-asserted-by":"publisher","unstructured":"Hsia O, Hinterndorfer M, Cowan AD et al (2024) Targeted protein degradation via intramolecular bivalent glues. Nature 627. https:\/\/doi.org\/10.1038\/s41586-024-07089-6","DOI":"10.1038\/s41586-024-07089-6"},{"key":"1541_CR23","doi-asserted-by":"publisher","unstructured":"Neklesa TK, Winkler JD, Crews CM (2017) Targeted protein degradation by PROTACs. Pharmacol Ther 174. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.027","DOI":"10.1016\/j.pharmthera.2017.02.027"},{"key":"1541_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","volume":"137","author":"C Surka","year":"2021","unstructured":"Surka C, Jin L, Mbong N et al (2021) CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137:661\u2013677. https:\/\/doi.org\/10.1182\/blood.2020008676","journal-title":"Blood"},{"key":"1541_CR25","doi-asserted-by":"publisher","unstructured":"Liu S, Qiao X, Wu S et al (2022) c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis: Int J Program Cell Death 27. https:\/\/doi.org\/10.1007\/s10495-022-01756-7","DOI":"10.1007\/s10495-022-01756-7"},{"key":"1541_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","volume":"11","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA (2021) Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 11:463. https:\/\/doi.org\/10.3390\/jpm11060463","journal-title":"J Pers Med"},{"key":"1541_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM (2024) Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis 15:413. https:\/\/doi.org\/10.1038\/s41419-024-06810-7","journal-title":"Cell Death Dis"},{"key":"1541_CR28","doi-asserted-by":"publisher","unstructured":"Nishida Y, Ishizawa J, Ayoub E, et al (2023) Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9:eadh1436. https:\/\/doi.org\/10.1126\/sciadv.adh1436","DOI":"10.1126\/sciadv.adh1436"},{"key":"1541_CR29","doi-asserted-by":"publisher","unstructured":"R\u00f6hner L, Ng YLD, Scheffold A et al (2021) Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V. Exp Hematol 93. https:\/\/doi.org\/10.1016\/j.exphem.2020.11.004","DOI":"10.1016\/j.exphem.2020.11.004"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01541-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:06:39Z","timestamp":1753934799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01541-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01541-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol (protocol code B16-4\u201320210901-0091\u201320240901, approved on 01-Sep-2021) was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai ChemPartner Co., Ltd. All procedures involving animals were conducted in strict accordance with relevant national regulations and institutional guidelines for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Liqiang Wang, Xin Cai, Yongsheng Wang, and Wei Hu hold equity at Chengdu Fendi Pharmaceutical Co., Ltd. Yang Kong, Qingchun Wu, and Wei Hu are employees of Chengdu Fendi Pharmaceutical Co., Ltd. The authors declare no additional conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}